Previous 10 | Next 10 |
2023-12-04 12:09:00 ET Summary TARS has launched a new drug, Xdemvy, for the treatment of Demodex blepharitis, with net product sales of $1.7M in the first five weeks following launch. TARS has readouts from three clinical trials due in the next four months, with one due in Q4'23....
2023-11-20 14:47:32 ET More on Tarsus Pharmaceuticals Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Earnings Call Transcript Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharma...
2023-11-10 18:59:09 ET Tarsus Pharmaceuticals, Inc. (TARS) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants David Nakasone - Head, IR Bobak Azamian - Chairman, CEO Aziz Mottiwala - CCO Jeff Farrow - CFO, CSO Conference Ca...
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 2.73% on the day to $14.13. Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development...
2023-11-09 17:08:17 ET More on Tarsus Pharmaceuticals Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharmaceuticals: Worthy Of A Small Bet Tarsus Pharmaceuticals' President &a...
2023-11-09 16:34:52 ET More on Tarsus Pharmaceuticals Xdemvy: Tarsus' Leading Asset In A Multi-Billion Market Landscape Tarsus Pharmaceuticals, Inc. - Barking Up The Wrong Tree Tarsus Pharmaceuticals: Worthy Of A Small Bet Tarsus Pharmaceuticals' President &a...
Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 million public equit...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Tarsus Pharmaceuticals Inc. (TARS) is expected to report $-1.4 for Q3 2023
2023-11-07 07:02:08 ET Summary Demodex Blepharitis (DB), Meibomian Gland Dysfunction (MGD), Dry Eye, Rosacea, and Lyme Disease are common conditions that can be treated with XDEMVY™. XDEMVY™ (lotilaner ophthalmic solution 0.25%) is the first FDA-approved treatment fo...
News, Short Squeeze, Breakout and More Instantly...
Tarsus Pharmaceuticals Inc. Company Name:
TARS Stock Symbol:
NASDAQ Market:
Tarsus Pharmaceuticals Inc. Website:
2024-06-03 08:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
IRVINE, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that management will participate in t...
2024-05-13 07:00:04 ET Oren Livnat from H.C. Wainwright issued a price target of $61.00 for TARS on 2024-05-13 06:01:00. The adjusted price target was set to $61.00. At the time of the announcement, TARS was trading at $37. TARS currently trades -5.98% versus its 52 week...